MedKoo Cat#: 206562 | Name: COH29
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

COH29 is an orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis.

Chemical Structure

COH29
CAS#1190932-38-7

Theoretical Analysis

MedKoo Cat#: 206562

Name: COH29

CAS#: 1190932-38-7

Chemical Formula: C22H16N2O5S

Exact Mass: 420.0780

Molecular Weight: 420.44

Elemental Analysis: C, 62.85; H, 3.84; N, 6.66; O, 19.03; S, 7.63

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 850.00 Ready to ship
200mg USD 1,550.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 3,650.00 Ready to ship
2g USD 5,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
COH29; COH-29; COH 29.
IUPAC/Chemical Name
N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide
InChi Key
LGGDLPSXAGQFSG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16N2O5S/c25-15-8-6-13(10-17(15)27)19-20(12-4-2-1-3-5-12)30-22(23-19)24-21(29)14-7-9-16(26)18(28)11-14/h1-11,25-28H,(H,23,24,29)
SMILES Code
OC1=C(O)C=C(C(NC2=NC(C3=CC(O)=C(O)C=C3)=C(C4=CC=CC=C4)S2)=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
COH29 inhibits α and β subunit of RNR with IC50s of 16 μM.
In vitro activity:
The effect of COH29 on DNA damage signaling was investigated in HCC1937 and HCC1937 + BRCA1 cells. COH29 induced significant phosphorylation of checkpoint kinase proteins Chk1 and Chk2 and increased the level of the DSB marker γ-H2AX in both cell lines (Fig. 3A). Notably, COH29 triggered more obvious signaling in HCC1937 cells compared with HCC1937 + BRCA1 cells in the same concentration range. A similar effect was also detected with HU treatment (Fig. 3B). As shown in Fig. 4A, induction of accumulation of p-ATM, γH2AX, foxo3, and its target protein p27 in the nucleus in response to COH29 was also observed. Furthermore, it was found that γH2AX and p-ATM colocalize with foxo3 in the nucleus by confocal immunofluorescence microscopy (Fig. 4, B and C). These data suggest COH29 activates DNA damage signaling and recruitment of activated-ATM and foxo3 at DNA damage sites. Reference: Mol Pharmacol. 2015 Jun;87(6):996-1005. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429719/
In vivo activity:
The antitumor activity of COH29 was investigated using murine tumor xenograft models of MOLT-4 leukemia cells or TOV11LD ovarian cancer cells, which were implanted and allowed to grow until the tumor was measurable at the subcutaneous site before oral administration of COH29 was begun. COH29 resulted in a dose-dependent inhibition of MOLT-4 tumor xenograft growth with twice-daily oral dosing at 50 mg/kg and 100 mg/kg, which was pronounced by Day 12 of treatment (Fig. 6A). Similarly, 7 days of treatment of mice bearing TOV11D xenografts with 200, 300, or 400 mg/kg/day COH29 resulted in a dose-dependent inhibition of tumor xenograft growth (Fig. 6B). Tumor growth was significantly inhibited compared with the control group. RNR activity in extracts of the MOLT-4 tumor xenografts shown in Fig. 6A was dramatically lower in the tumors from mice that had been treated with COH29 for 12 days (Fig. 6D), confirming that COH29 inhibits its target in vivo. Consistent with decreased RNR activity, intratumoral dNTP pools were also decreased in xenografts from mice treated with COH29 vs. control (Fig. 6E-G). Reference: Cancer Res. 2013 Nov 1;73(21):6484-93. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823501/
Solvent mg/mL mM comments
Solubility
DMSO 45.0 107.03
Ethanol 10.0 23.78
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 420.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol. 2015 Jun;87(6):996-1005. doi: 10.1124/mol.114.094987. Epub 2015 Mar 26. PMID: 25814515; PMCID: PMC4429719. 2. Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26. PMID: 24072748; PMCID: PMC3823501. 3. Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17. PMID: 30996073; PMCID: PMC6820162.
In vitro protocol:
1. Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol. 2015 Jun;87(6):996-1005. doi: 10.1124/mol.114.094987. Epub 2015 Mar 26. PMID: 25814515; PMCID: PMC4429719. 2. Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26. PMID: 24072748; PMCID: PMC3823501.
In vivo protocol:
1. Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26. PMID: 24072748; PMCID: PMC3823501. 2. Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17. PMID: 30996073; PMCID: PMC6820162.
1: Chen YR, Tsou B, Hu S, Ma H, Liu X, Yen Y, Ann DK. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells. Oncotarget. 2016 Jan 12;7(2):1984-99. doi: 10.18632/oncotarget.6539. PubMed PMID: 26675256; PubMed Central PMCID: PMC4811511. 2: Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol. 2015 Jun;87(6):996-1005. doi: 10.1124/mol.114.094987. Epub 2015 Mar 26. PubMed PMID: 25814515; PubMed Central PMCID: PMC4429719. 3: Zhang H, Liu X, Warden CD, Huang Y, Loera S, Xue L, Zhang S, Chu P, Zheng S, Yen Y. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer. 2014 Sep 11;14:664. doi: 10.1186/1471-2407-14-664. PubMed PMID: 25213022; PubMed Central PMCID: PMC4171582. 4: Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26. PubMed PMID: 24072748; PubMed Central PMCID: PMC3823501.